Grant: Operating Grant: 14th JPIAMR transnational call for research projects (2022)
University of Alberta
$278,485.00
LyophilizeD fecal micrObiome traNsfer for primAry closTridioides difficilE infection (DONATE study): a multicenter randomized controlled trial
FY 2022-23
Summary
Primary Clostridioides difficile infection (pCDI) is a gastrointestinal infection that presents with diarrhea, fever and abdominal pain and is often resistant to antibiotic therapy. pCDI is often a consequence of previous exposure to antibiotics that disrupt the balance of healthy microbes that reside in our gut. Fecal microbiota transplantation (FMT), the introduction of a healthy microbial community from a healthy donor, has been shown to be safe and highly effective in patients who experience recurrence of CDI, but was not vigorously tested in primary infection. FMT can also fight other deleterious microbes that might reside in the gut. Since FMT contains live bacteria, it needs to be kept frozen until administration. We have developed a dry compound that does not need freezing (Lyo-FMT) and aim to assess its efficacy for pCDI. This easy-to-administer product will restore the healthy bacterial community, fight infection and reduce the use of antibiotics. If effective, this study will revolutionize the treatment of this worldwide distributed infection.
Department
Program
Operating Grant: 14th JPIAMR transnational call for research projects (2022)
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
467419
Name
Kao Dina H
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Fondazione Regionale per la Ricerca Biomedica (Milan, Italy); Israeli Ministry of Health; Medical Research Council (UK); National Research, Development and Innovation Office (Budapest, Hungary); Research Council of Lithuania (RCL); Ministero della Salute (Italy)
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Special Cases
Projecttitle
LyophilizeD fecal micrObiome traNsfer for primAry closTridioides difficilE infection (DONATE study): a multicenter randomized controlled trial
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$278,485
Cihrequipment2
$0
Programname2
Operating Grant: 14th JPIAMR transnational call for research projects (2022)
Keyworddelim
Clinical Trial; Clostridioides Difficile Infection; Fecal Transplant
Abstract
Primary Clostridioides difficile infection (pCDI) is a gastrointestinal infection that presents with diarrhea, fever and abdominal pain and is often resistant to antibiotic therapy. pCDI is often a consequence of previous exposure to antibiotics that disrupt the balance of healthy microbes that reside in our gut. Fecal microbiota transplantation (FMT), the introduction of a healthy microbial community from a healthy donor, has been shown to be safe and highly effective in patients who experience recurrence of CDI, but was not vigorously tested in primary infection. FMT can also fight other deleterious microbes that might reside in the gut. Since FMT contains live bacteria, it needs to be kept frozen until administration. We have developed a dry compound that does not need freezing (Lyo-FMT) and aim to assess its efficacy for pCDI. This easy-to-administer product will restore the healthy bacterial community, fight infection and reduce the use of antibiotics. If effective, this study will revolutionize the treatment of this worldwide distributed infection.
Competitiondate
202207
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kao, Dina H
Approvedterm
3 ans 0 mois
Cihrcontribution2
Antimicrobial Resistance~ $278,485~ $0~
